0001662252-18-000034.txt : 20180220 0001662252-18-000034.hdr.sgml : 20180220 20180220144950 ACCESSION NUMBER: 0001662252-18-000034 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 45 CONFORMED PERIOD OF REPORT: 20171231 FILED AS OF DATE: 20180220 DATE AS OF CHANGE: 20180220 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Regenicin, Inc. CENTRAL INDEX KEY: 0001412659 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-146834 FILM NUMBER: 18624246 BUSINESS ADDRESS: STREET 1: 10 HIGH COURT CITY: LITTLE FALLS STATE: NJ ZIP: 07424 BUSINESS PHONE: (973) 557-8914 MAIL ADDRESS: STREET 1: 10 HIGH COURT CITY: LITTLE FALLS STATE: NJ ZIP: 07424 FORMER COMPANY: FORMER CONFORMED NAME: Windstar Inc. DATE OF NAME CHANGE: 20070918 10-Q 1 rgin10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

[X]	Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

	For the quarterly period ended December 31, 2017

[ ]	Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934

	For the transition period from to __________

	Commission File Number: 333-146834

Regenicin, Inc.
(Exact name of registrant as specified in its charter)

Nevada	27-3083341
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

10 High Court, Little Falls, NJ

(Address of principal executive offices)

(973) 557-8914

(Registrant’s telephone number)

_______________________________________________________________

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days

[ ] Yes [X] No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). [ ] Yes [X] No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

[ ] Large accelerated filer

[ ] Non-accelerated filer

[ ] Accelerated filer

[X] Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [ ] Yes [X] No

State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 153,483,050 as of February 12, 2018.

Table of Contents

	TABLE OF CONTENTS	Page

PART I – FINANCIAL INFORMATION

Item 1:	Financial Statements	3
Item 2:	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4
Item 3:	Quantitative and Qualitative Disclosures About Market Risk	6
Item 4:	Controls and Procedures	6
PART II – OTHER INFORMATION
Item 1:	Legal Proceedings	7
Item 1A:	Risk Factors	7
Item 2:	Unregistered Sales of Equity Securities and Use of Proceeds	7
Item 3:	Defaults Upon Senior Securities	7
Item 4:	Mine Safety Disclosures	7
Item 5:	Other Information	7
Item 6:	Exhibits	7

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1.

Financial Statements

Our consolidated financial statements included in this Form 10-Q are as follows:

F-1	Consolidated Balance Sheets as of December 31, 2017 (unaudited) and September 30, 2017;
F-2	Consolidated Statements of Operations for the three months ended December 31, 2017 and 2016 (unaudited);
F-3	Consolidated Statements of Comprehensive Loss for the three months ended December 31, 2017 and 2016 (unaudited);
F-4	Consolidated Statements of Cash Flows for the three months ended December 31, 2017 and 2016 (unaudited); and
F-5	Notes to Consolidated Financial Statements.

These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the SEC instructions to Form 10-Q. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the interim period ended December 31, 2017 are not necessarily indicative of the results that can be expected for the full year.

Table of Contents

REGENICIN, INC. AND SUBSIDIARY

CONSOLIDATED BALANCE SHEETS

	December 31,			September 30,
	2017			2017
		(UNAUDITED)
ASSETS
CURRENT ASSETS
Cash	$	7,320		$	19,201
Prepaid expenses and other current assets		40,004			60,592
Common stock of Amarantus Corporation		35,250			8,000
Total current assets		82,574			87,793
Due from related party		—			—
Total assets	$	82,574		$	87,793

LIABILITIES AND STOCKHOLDERS' DEFICIENCY
CURRENT LIABILITIES
Accounts payable	$	275,402		$	280,961
Accrued expenses - other		300,574			298,476
Accrued salaries - officers		1,852,251			1,707,001
Note payable - insurance financing		26,690			37,800
Bridge financing		175,000			175,000
Loan payable		10,000			10,000
Loans payable - officer		64,958			20,000
Total current and total liabilities		2,704,875			2,529,238

STOCKHOLDERS' DEFICIENCY
Series A 10% Convertible Preferred stock, $0.001 par value, 5,500,000 shares authorized; 885,000 issued and outstanding		885			885
Common stock, $0.001 par value; 200,000,000 shares authorized; 157,911,410 issued and 153,483,050 outstanding		157,914			157,914
Additional paid-in capital		10,177,515			10,177,515
Accumulated deficit		(12,981,937	)		(12,773,831	)
Accumulated other comprehensive income		27,750			500
Less: treasury stock; 4,428,360 shares at par		(4,428	)		(4,428	)
Total stockholders' deficiency		(2,622,301	)		(2,441,445	)
Total liabilities and stockholders' deficiency	$	82,574		$	87,793

See Notes to Consolidated Financial Statements.

F-1

Table of Contents

REGENICIN, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF OPERATIONS

	Three Months Ended			Three Months Ended
	December 31,			December 31,
	2017			2016
	(UNAUDITED)			(UNAUDITED)

Revenues	$	—		$	—

Operating expenses
Research and development		—			5,284
General and administrative		203,039			290,027
Total operating expenses		203,039			295,311

Operating loss before other operating income		(203,039	)		(295,311	)
Other operating income - reversal of accounts payable		—			15,000
Loss from operations		(203,039	)		(280,311	)

Other income (expenses)
Interest expense		(5,067	)		(4,411	)
Interest income		—			2,900
Total other income (expenses)		(5,067	)		(1,511	)
Net loss		(208,106	)		(281,822	)
Preferred stock dividends		(17,845	)		(17,845	)
Net loss attributable to common stockholders	$	(225,951	)	$	(299,667	)

Loss per share:
Basic	$	(0.00	)	$	(0.00	)
Diluted	$	(0.00	)	$	(0.00	)
Weighted average number of shares outstanding
Basic		153,483,050			153,483,050
Diluted		153,483,050			153,483,050

See Notes to Consolidated Financial Statements.

F-2

Table of Contents

REGENICIN, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

	Three Months Ended			Three Months Ended
	December 31,			December 31,
	2017			2016
	(UNAUDITED)			(UNAUDITED)
Net loss	$	(208,106	)	$	(281,822	)
Other comprehensive income (loss):
Change in unrealized gain (loss) on available-for-sale securities, net of income taxes		27,250			(800	)
Comprehensive loss	$	(180,856	)	$	(282,622	)

See Notes to Consolidated Financial Statements.

F-3

Table of Contents

REGENICIN, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CASH FLOWS

	Three Months Ended			Three Months Ended
	December 31,			December 31,
	2017			2016
	(UNAUDITED)			(UNAUDITED)
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(208,106	)	$	(281,822	)
Adjustments to reconcile net loss to net cash used in operating activities:
Accrued interest on notes and loans payable		4,411			4,411
Accrued Interest income on due from related party		—			(2,892	)
Reversal of accounts payable		—			(15,000	)
Changes in operating assets and liabilities
Prepaid expenses and other current assets		20,586			8,976
Accounts payable		(5,557	)		16,924
Accrued expenses		(2,313	)		(31,293	)
Accrued salaries - officers		145,250			145,250
Net cash used in operating activities		(45,729	)		(155,446	)

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds of loans from officers		44,958			—
Repayments of notes payable - insurance financing		(11,110	)
Repayment of loans from officers		—			(13,009	)
Net cash provided by (used in) financing activities		33,848			(13,009	)

NET DECREASE IN CASH		(11,881	)		(168,455	)
CASH - BEGINNING OF PERIOD		19,201			218,847
CASH - END OF PERIOD	$	7,320		$	50,392

Supplemental disclosures of cash flow information:
Cash paid for interest	$	—		$	—
Cash paid for taxes	$	500		$	—

See Notes to Consolidated Financial Statements.

F-4

Table of Contents

REGENICIN, INC. AND SUBSIDIARY

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 1 - THE COMPANY

Windstar, Inc. was incorporated in the state of Nevada on September 6, 2007. On July 19, 2010, the Company amended its Articles of Incorporation to change the name of the Company to Regenicin, Inc. (“Regenicin”). In September 2013, Regenicin formed a new wholly-owned subsidiary for the sole purpose of conducting research in the State of Georgia (together, the “Company”). The subsidiary has no activity since its formation due to the lack of funding. The Company’s original business was the development of a purification device. Such business was assigned to the Company’s former management in July 2010. The Company adopted a new business plan and intended to develop and commercialize a potentially lifesaving technology by the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures.

The Company entered into a Know-How License and Stock Purchase Agreement (the “Know-How SPA”) with Lonza Walkersville, Inc. (“Lonza Walkersville”) on July 21, 2010. Pursuant to the terms of the Know-How SPA, the Company paid Lonza Walkersville $3,000,000 and, in exchange, the Company was to receive an exclusive license to use certain proprietary know-how and information necessary to develop and seek approval by the U.S. Food and Drug Administration (“FDA”) for the commercial sale of technology held by the Cutanogen Corporation (“Cutanogen”), a subsidiary of Lonza Walkersville. Additionally, pursuant to the terms of the Know-How SPA, the Company was entitled to receive certain related assistance and support from Lonza Walkersville upon payment of the $3,000,000. Under the Know-How SPA, once FDA approval was secured for the commercial sale of the technology, the Company would be entitled to acquire Cutanogen, Lonza Walkersville’s subsidiary, for $2,000,000 in cash. After prolonged attempts to negotiate disputes with Lonza Walkersville failed, on September 30, 2013, the Company filed a lawsuit against Lonza Walkersville, Lonza Group Ltd. and Lonza America, Inc. (“Lonza America”) in Fulton County Superior Court in the State of Georgia.

On November 7, 2014, the Company entered into an Asset Sale Agreement (the “Sale Agreement”) with Amarantus Bioscience Holdings, Inc., (“Amarantus”). Under the Sale Agreement, the Company agreed to sell to Amarantus all of its rights and claims in the litigation currently pending in the United States District Court for the District of New Jersey against Lonza Walkersville and Lonza America, Inc. (the “Lonza Litigation”). This includes all of the Cutanogen intellectual property rights and any Lonza manufacturing know-how technology. In addition, the Company agreed to sell the PermaDerm® trademark and related intellectual property rights associated with it. The purchase price paid by Amarantus was: (i) $3,600,000 in cash, and (ii) shares of common stock in Amarantus having a value of $3,000,000 at the date of the transaction.

The Company used the net proceeds of the transaction to fund development of cultured cell technology and to pursue approval of the products through the FDA as well as for general and administrative expenses. The Company has been developing its own unique cultured skin substitute since the Company received Lonza’s termination notice.

F-5

Table of Contents

NOTE 2 - BASIS OF PRESENTATION

Interim Financial Statements:

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended December 31, 2017 are not necessarily indicative of the results that may be expected for the year ending September 30, 2018. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended September 30, 2017, as filed with the Securities and Exchange Commission.

Going Concern:

The Company's consolidated financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred cumulative losses and has an accumulated deficit of approximately $13.0 million from inception, expects to incur further losses in the development of its business and has been dependent on funding operations through the issuance of convertible debt, private sale of equity securities, and the proceeds from the Asset Sale. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The Company used the proceeds from the Asset Sale to fund operations. Currently management plans to finance operations through the private or public placement of debt and/or equity securities. However, no assurance can be given at this time as to whether the Company will be able to obtain such financing. The consolidated financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Financial Instruments and Fair Value Measurement:

The Company measures fair value of its financial assets on a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

• Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

• Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable or inputs that can be corroborated by observable market data for substantially the full term of the assets or liabilities.

• Level 3 - Unobservable inputs which are supported by little or no market activity.

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

The carrying value of cash, prepaid expenses and other current assets, accounts payable, accrued expenses and all loans and notes payable in the Company’s consolidated balance sheets approximated their values as of December 31, 2017 and September 30, 2017 due to their short-term nature.

Common stock of Amarantus represents equity investments in common stock that the Company classifies as available for sale. Such investments are carried at fair value in the accompanying consolidated balance sheets. Fair value is determined under the guidelines of GAAP which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. Realized gains and losses, determined using the first-in, first-out (FIFO) method, are included in net income (loss). Unrealized gains and losses considered to be temporary are reported as other comprehensive income (loss) and are included in stockholders equity. Other than temporary declines in the fair value of investment is included in other income (expense) on the statement of operations.

The common stock of Amarantus is valued at the closing price reported on the active market on which the security is traded. This valuation methodology is considered to be using Level 1 inputs. The total value of Amarantus common stock at December 31, 2017 is $35,250. The unrealized gain (loss) for the three months ended December 31, 2017 and 2016 was $27,250 and $(800) net of income taxes, respectively, and was reported as a component of comprehensive loss.

F-6

Table of Contents

Recently Issued Accounting Pronouncements:

In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities”. The new standard principally affects accounting standards for equity investments, financial liabilities where the fair value option has been elected, and the presentation and disclosure requirements for financial instruments. Upon the effective date of the new standards, all equity investments in unconsolidated entities, other than those accounted for using the equity method of accounting, will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification and therefore, no changes in fair value will be reported in other comprehensive income (loss) for equity securities with readily determinable fair values. The new guidance on the classification and measurement will be effective for public business entities in fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, and early adoption of certain items is permitted. The Company is currently evaluating the impact of adopting this guidance.

All other recent pronouncements issued by the FASB or other authoritative standards groups with future effective dates are either not applicable or are not expected to be significant to the consolidated financial statements of the Company.

NOTE 3 - LOSS PER SHARE

Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share gives effect to dilutive convertible securities, options, warrants and other potential common stock outstanding during the period; only in periods in which such effect is dilutive.

The following weighted average securities have been excluded from the calculation of net loss per share for the quarters ended December 31, 2017 and 2016, as the exercise price was greater than the average market price of the common shares:

			2017				2016
	Warrants			722,500				722,500

The following weighted average securities have been excluded from the calculation even though the exercise price was less than the average market price of the common shares because the effect of including these potential shares was anti-dilutive due to the net loss incurred during the quarters ended December 31, 2017 and 2016:

	2017		2016
Options		10,393,754		5,150,979
Convertible Preferred Stock		8,850,000		8,850,000

The effects of options and warrants on diluted earnings per share are reflected through the use of the treasury stock method and the excluded shares that are “in the money” are disclosed above in that manner.

F-7

Table of Contents

NOTE 4 – DUE FROM RELATED PARTY

The Company expects to purchase “Closed Herd” collagen from Pure Med Farma, LLC (“PureMed”), a development stage company in which the company’s CEO and CFO are member - owners. The Company and Pure Med entered into a three year supply agreement on October 16, 2016 naming Pure Med as the exclusive provider of collagen to the Company. The Company has agreed to assist PureMed by providing consultants to work on certain tasks in order to gain FDA approval. Such consultants’ costs would be reimbursed by PureMed. On December 15, 2016, PureMed issued a note in the amount of $64,622 representing the advances for consultants through that date. Under the terms of the note, interest accrued at 8% per annum and was payable on or before December 15, 2017. The balance of the note plus accrued interest of $7,308 was repaid in full in May 2017.

NOTE 5 - LOANS PAYABLE

Loan Payable:

In February 2011, an investor advanced $10,000. The loan does not bear interest and is due on demand. At both December 31, 2017 and September 30, 2017, the loan payable totaled $10,000.

Loans Payable - Officer:

Loans payable - officer consists of the following:

• In September 2017, John Weber, the Company’s Chief Financial Officer, made an advance to the Company of $10,000. In November and December additional advances were made totaling $42,958. The loans do not bear interest and are due on demand.

• In September 2017, J. Roy Nelson, the Company’s Chief Science Officer, made an advance to the Company of $10,000. In November an additional advance was made in the amount of $2,000. The loans do not bear interest and are due on demand.

NOTE 6 - BRIDGE FINANCING

On December 21, 2011, the Company issued a $150,000 promissory note to an individual. The note bore interest so that the Company would repay $175,000 on the maturity date of June 21, 2012, which correlated to an effective rate of 31.23%. Additional interest of 10% was charged on any late payments. The note was not paid at the maturity date and the Company is incurring additional interest as described above. At both December 31, 2017 and September 30, 2017, the note balance was $175,000. Interest expense was $4,411 for both quarters ended December 31, 2017 and 2016. Accrued interest on the note was $96,800 and $92,389 as of December 31, 2017 and September 30, 2017, respectively, and is included in Accrued expenses - other in the accompanying balance sheet.

F-8

Table of Contents

NOTE 7 - INCOME TAXES

The Company did not incur current tax expense for the three months ended December 31, 2017 and 2016.

At December 31, 2017, the Company had available approximately $4.6 million of net operating loss carry forwards (“NOLs”) which expire in the years 2029 through 2037. However, the use of the NOLs generated prior to September 30, 2011 totaling $0.7 million is limited under Section 382 of the Internal Revenue Code. Section 382 of the Internal Revenue Code of 1986, as amended (the Code), imposes an annual limitation on the amount of taxable income that may be offset by a corporation’s NOLs if the corporation experiences an “ownership change” as defined in Section 382 of the Code.

On December 22, 2017, new tax legislation came into effect. The provisions are generally effective for years beginning on or after January 1, 2018. The most impactful item to the Company in the new law is the change in federal tax rate from 34% to 21%. This will reduce the gross deferred tax assets prior to existing full valuation allowance from an effective combined federal/state/local rate of 40% to an effective rate of 27%. The provision and disclosures for the period ended December 31, 2017 reflect the new tax legislation.

Significant components of the Company’s deferred tax assets at December 31, 2017 and September 30, 2017 are as follows:

	December 31, 2017			September 30, 2017
Net operating loss carry forwards	$	1,217,622		$	1,780,508
Unrealized loss		807,975			1,197,000
Stock based compensation		27,070			40,104
Accrued expenses		500,108			686,800
Total deferred tax assets		2,552,775			3,704,412
Valuation allowance		(2,552,775	)		(3,704,412	)
Net deferred tax assets	$	—		$	—

Due to the uncertainty of their realization, a valuation allowance has been established for all of the income tax benefit for these deferred tax assets.

At both December 31, 2017 and September 30, 2017, the Company had no material unrecognized tax benefits and no adjustments to liabilities or operations were required. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company recognizes interest and penalties related to uncertain tax positions in general and administrative expense. As of December 31, 2017 and September 30, 2017 the Company has not recorded any provisions for accrued interest and penalties related to uncertain tax positions.

The Company files its federal income tax returns under a statute of limitations. The 2014 through 2017 tax years generally remain subject to examination by federal tax authorities.

F-9

Table of Contents

NOTE 8 - STOCKHOLDERS’ DEFICIENCY

Preferred Stock:

Series A

At both December 31, 2017 and September 30, 2017, 885,000 shares of Series A Preferred Stock (“Series A Preferred”) were outstanding.

Series A Preferred pays a dividend of 8% per annum on the stated value and has a liquidation preference equal to the stated value of the shares ($885,000 liquidation preference as of December 31, 2017 and September 30, 2017 plus dividends in arrears as per below). Each share of Series A Preferred Stock has an initial stated value of $1 and is convertible into shares of the Company’s common stock at the rate of 10 for 1.

The Series A Preferred Stock was marketed through a private placement memorandum that included a reference to a ratchet provision which would have allowed the holders of the stock to claim a better conversion rate based on other stock transactions conducted by the Company during the three year period following the original issuance of the shares. The Certificate of Designation does not contain a ratchet provision. Certain of the stock related transactions consummated by the Company during this time period may have triggered this ratchet provision, and thus created a claim by holders of the Series A Preferred Stock who purchased based on this representation for a greater conversion rate than initially provided. The Company is currently negotiating with some of the remaining Series A holders regarding this claim and their conversation rate of their Series A Preferred Stock. Changes to the preferred stock conversion ratio may result in modification or extinguishment accounting. That may result in a deemed preferred stock dividend which would reduce net income available to common stockholders in the calculation of earnings per share. Certain of the smaller Series A holders have already converted or provided notice of conversion of their shares. In respect of this claim, the Company and its outside counsel determined that it is not possible to offer an opinion regarding the outcome. An adverse outcome could materially increase the accumulated deficit.

The dividends are cumulative commencing on the issue date when and if declared by the Board of Directors. As of December 31, 2017, and September 30, 2017, dividends in arrears were $481,682 ($.54 per share) and $463,837 ($.52 per share), respectively.

Series B

On January 23, 2012, the Company designated a new class of preferred stock called Series B Convertible Preferred Stock (“Series B Preferred”). Four million shares have been authorized with a liquidation preference of $2.00 per share. Each share of Series B Preferred is convertible into ten shares of common stock. Holders of Series B Convertible Preferred Stock have a right to a dividend (pro-rata to each holder) based on a percentage of the gross revenue earned by the Company in the United States, if any, and the number of outstanding shares of Series B Convertible Preferred Stock, as follows: Year 1 - Total Dividend to all Series B holders = .03 x Gross Revenue in the U.S. Year 2 - Total Dividend to all Series B holders = .02 x Gross Revenue in the U.S. Year 3 - Total Dividend to all Series B holders = .01 x Gross Revenue in the U.S. At December 31, 2017, no shares of Series B Preferred are outstanding.

F-10

Table of Contents

NOTE 9 – SALE OF ASSET

On November 7, 2014, the Company entered into a Sale Agreement, as amended on January 30, 2015, with Amarantus. See Note 1. Under the Sale Agreement, the Company agreed to sell to Amarantus all of its rights and claims in the Lonza Litigation. These include all of the Cutanogen intellectual property rights and any Lonza manufacturing know-how technology. In addition, the Company had agreed to sell its PermaDerm® trademark and related intellectual property rights associated with it. The Company also granted to Amarantus an exclusive five (5) year option to license any engineered skin designed for the treatment of patients designated as severely burned by the FDA developed by the Company. Amarantus can exercise this option at a cost of $10,000,000 plus a royalty of 5% on gross revenues in excess of $150 million. As of December 31, 2017, the option has not been exercised.

NOTE 10 - RELATED PARTY TRANSACTIONS

The Company’s principal executive offices are located in Little Falls, New Jersey. The headquarters is located in the offices of McCoy Enterprises LLC, an entity controlled by Mr. McCoy. The office is attached to his residence but has its own entrances, restroom and kitchen facilities.

The Company also maintains an office at Carbon & Polymer Research Inc. ("CPR") in Pennington, New Jersey, which is the Company's materials and testing laboratory. An employee of the Company is an owner of CPR. On May 16, 2016, the Company entered into an agreement with CPR in which CPR will supply the collagen scaffolds used in the Company's production of the skin tissue. The contract contains a most favored customer clause guaranteeing the Company prices equal or lower than those charged to other customers. The Company has not yet made purchases from CPR.

No rent is charged for either premise.

NOTE 11 - SUBSEQUENT EVENTS

Management has evaluated subsequent events through the date of this filing.

F-11

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

Overview

Overview

As we move into 2018, the Company will continue to pursue its goal of obtaining FDA approval for its product NovaDerm. The product is well positioned to enter clinical trials. At this point the most significant gating item is financing. We have been consistently working with several investor groups and we remain confident that the necessary funding will be secured.

NovaDerm is well positioned to enter clinical trials due to the following:

NovaDerm has an extensive documented history of clinical research.

Additional independent product research has demonstrated the products superiority.

NovaDerm has been awarded Orphan Product Designation by the FDA, which indicates the value and humanitarian benefits of the product.

The positive results of the Pre-IND Application meeting between the Company and the FDA, in which both parties fully agreed on a pathway forward to enter the clinical trials.

The Company has entered into two critical contracts to secure Closed Herd collagen and to fabricate the collagen scaffolds, the platform on which NovaDerm is grown.

The company has selected a Clinical Research Organization, (CRO), to assist in the management of the clinical trials and the Company has identified a Principal Lead Investigator, a medical advisor for the clinical trials.

In conjunction with CRO, two clinical sites will be selected to host the clinical trials.

Based on our agreement with the FDA, the clinical trials call for 3 patients initially and then 7 additional patients. The entire episode of care is estimated to be 1-4 months, depending on the severity of the burn. NovaDerm’s protocol is similiar to that currently performed with split thickness allograph and other temporary skin substitutes. Therefore, there is no additional physician training required. The chance of an immune system rejection is greatly reduced because NovaDerm is produced from the patient’s own cells. Finally, patient recruitment should be very fast because it will require fewer patients because of it’s Orphan status. When NovaDerm is approved to start clinical trials, NovaDerm may be used by any of the 150 burn centers for Humanitarian Use as long as the burn center agrees to follow the clinical trial protocol on file with the IND.

As aforementioned, NovaDerm is well positioned to enter and successfully complete the clinical trials for FDA product approval. Currently, our main task is to raise the adequate funding to complete the IND application and begin the clinical trials, which we estimate at $3.5 million to $4.5 million.

Table of Contents

Results of Operations for the Three Months Ended December 31, 2017 and 2016

We generated no revenues from September 6, 2007 (date of inception) to December 31, 2017. We do not expect to generate revenues until we are able to obtain FDA approval of our product and thereafter successfully market and sell the product.

We incurred operating expenses of $203,039 for the three months ended December 31, 2017, compared with operating expenses of $295,311 for the three months ended December 31, 2016. General and administrative expenses accounted for all of our operating expenses, for the three months ended December 31, 2017. The major difference and shift in operating expenses from the three months ended December 31, 2016 was accounted for by a reduction of general and administrative expense of $86,988, mainly due to a decrease in consulting expenses.

Net other expense was $5,067 for the three months ended December 31, 2017, as compared to net other expense of $1,511 for the three months ended December 31, 2016. Other income and expenses for the three months ended December 31, 2017 consisted of only interest expense of $5,067. Other income and expenses for the same period ended December 31, 2016 consisted of interest income of $2,900, and interest expense of $4,411.

After deduction for preferred stock dividends of $17,845 for each of the three months ended December 31, 2017 and 2016, we recorded a net loss attributable to common stockholders of $225,951 for the three months ended December 31, 2017. By comparison, we recorded a net loss attributable to common stockholders of $299,667 for the three months ended December 31, 2016.

Liquidity and Capital Resources

As of December 31, 2017, we had cash of $7,320 and total current assets of $82,574. As of December 31, 2017, we had current liabilities of $2,704,875. We therefore had a working capital deficit of $2,622,301.

Operating activities used $45,729 in cash for the three months ended December 31, 2017. Cash flows from financing activities includes proceeds from loans from officers of $44,958, net of repayments of notes payable of $11,110.

Investing activities provided no cash or cost during the reported period. We note that the value of the shares of Amarantus we obtained and which created income from that sale of assets transaction have declined significantly in value since the consummation of the agreement.

We have issued various promissory notes to meet our short term demands, the terms of which are provided in the notes to the consolidated financial statements accompanying this report. While this source of bridge financing has been helpful in the short term to meet our financial obligations, we will need additional financing to fund our operations, continue with the FDA approval process, and implement our business plan. Our long term financial needs are estimated at about $8-10 million.

Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve months. We intend to fund operations through increased debt and/or equity financing arrangements, which may be insufficient to fund expenditures or other cash requirements. We plan to seek additional financing in a private equity or debt offering to secure funding for operations. There can be no assurance that we will be successful in raising additional funding. If we are not able to secure additional funding, the implementation of our business plan will be impaired. There can be no assurance that such additional financing will be available to us on acceptable terms or at all.

Off Balance Sheet Arrangements

As of December 31, 2017, there were no off balance sheet arrangements.

Going Concern

Our consolidated financial statements have been prepared assuming that we will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. We have incurred operating losses from inception, expect to incur further losses in the development of our business, and have been dependent on funding operations through the issuance of convertible debt and private sale of equity securities. These conditions raise substantial doubt about our ability to continue as a going concern. Management’s plans include continuing to finance operations through the private or public placement of debt and/or equity securities and the reduction of expenditures. However, no assurance can be given at this time as to whether we will be able to achieve these objectives. The consolidated financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk

A smaller reporting company is not required to provide the information required by this Item.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of December 31, 2017. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2017, our disclosure controls and procedures were not effective due to the presence of material weaknesses in internal control over financial reporting.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified the following material weaknesses which have caused management to conclude that, as of December 31, 2017, our disclosure controls and procedures were not effective: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

Remediation Plan to Address the Material Weaknesses in Internal Control over Financial Reporting

Our company plans to take steps to enhance and improve the design of our internal controls over financial reporting. During the period covered by this quarterly report on Form 10-Q, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we plan to implement the following changes during our fiscal year ending September 30, 2018 assuming we are able to obtain necessary funding: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

We are unable to remedy our controls related to the inadequate segregation of duties and ineffective risk management until we receive financing to hire additional employees.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the three months ended December 31, 2017 that have materially affected, or are reasonable likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

We are not a party to any pending legal proceeding. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.

Item 1A. Risk Factors

A smaller reporting company is not required to provide the information required by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The information set forth below relates to our issuances of securities without registration under the Securities Act of 1933 during the reporting period which were not previously included in a Quarterly Report on Form 10-Q or Current Report on Form 8-K.

For the three months ended December 31, 2017, we issued no shares of common stock.

Item 3. Defaults upon Senior Securities

None

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None

Item 6. Exhibits

Exhibit Number	Description of Exhibit
31.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101**	The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2017 formatted in Extensible Business Reporting Language (XBRL).
**Provided herewith

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Regenicin, Inc.

Date:	February 20, 2018

By:	/s/ Randall McCoy
	Randall McCoy
Title:	Chief Executive Officer and Director

EX-31.1 2 ex31_1.htm EX-31.1

CERTIFICATIONS

I, Randall McCoy, certify that;

I have reviewed this quarterly report on Form 10-Q for the quarter ended December 31, 2017 of Regenicin, Inc (the “registrant”);

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 20, 2018

/s/ Randall McCoy

By: Randall McCoy

Title: Chief Executive Officer

EX-31.2 3 ex31_2.htm EX-31.2

CERTIFICATIONS

I, John J. Weber, certify that;

I have reviewed this quarterly report on Form 10-Q for the quarter ended December 31, 2017 of Regenicin, Inc (the “registrant”);

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 20, 2018

/s/ John J. Weber

By: John J. Weber

Title: Chief Financial Officer

EX-32.1 4 ex32_1.htm EX-32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND

CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly Report of Regenicin, Inc (the “Company”) on Form 10-Q for the quarter ended December 31, 2017 filed with the Securities and Exchange Commission (the “Report”), I, Randall McCoy, Chief Executive Officer of the Company, and, I John J. Weber, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) and Section 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the consolidated financial condition of the Company as of the dates presented and the consolidated result of operations of the Company for the periods presented.

By:	/s/ Randall McCoy
Name:	Randall McCoy
Title:	Principal Executive Officer and Director
Date:	February 20, 2018

By:	/s/ John J. Weber
Name:	John J. Weber
Title:	Principal Financial Officer and Director
Date:	February 20, 2018

This certification has been furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

EX-101.INS 5 rgin-20171231.xml XBRL INSTANCE FILE 0001412659 2017-10-01 2017-12-31 0001412659 2018-02-12 0001412659 2017-09-30 0001412659 2017-12-31 0001412659 us-gaap:SeriesAPreferredStockMember 2017-09-30 0001412659 us-gaap:SeriesAPreferredStockMember 2017-12-31 0001412659 us-gaap:SeriesBPreferredStockMember 2017-09-30 0001412659 RGIN:KnowHowSPAMember 2017-10-01 2017-12-31 0001412659 RGIN:PromissoryNote2Member 2017-10-01 2017-12-31 0001412659 RGIN:PromissoryNote2Member 2017-09-30 0001412659 RGIN:ExclusionsFromDilutedCalculationsMember 2016-12-31 0001412659 RGIN:SaleAgreementAmendmentMember 2017-10-01 2017-12-31 0001412659 RGIN:SaleAgreementMember 2017-10-01 2017-12-31 0001412659 us-gaap:SeriesAPreferredStockMember 2017-10-01 2017-12-31 0001412659 2016-10-01 2016-12-31 0001412659 RGIN:SupplyAgreementMember 2016-10-01 2016-12-31 0001412659 RGIN:SupplyAgreementMember 2016-12-31 0001412659 RGIN:ExclusionsFromDilutedCalculations2Member 2016-12-31 0001412659 us-gaap:ChiefFinancialOfficerMember 2017-12-31 0001412659 RGIN:ChiefScienceOfficerMember 2017-12-31 0001412659 us-gaap:SeriesBPreferredStockMember 2017-12-31 0001412659 2016-09-30 0001412659 2016-12-31 0001412659 RGIN:ExclusionsFromCalculationsMember 2017-12-31 0001412659 RGIN:ExclusionsFromCalculations2Member 2017-12-31 0001412659 RGIN:ShareholderMember 2017-12-31 0001412659 RGIN:ShareholderMember 2016-12-31 0001412659 RGIN:PromissoryNote2Member 2016-10-01 2016-12-31 0001412659 RGIN:PromissoryNote2Member 2017-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure 2017 10-Q 2017-12-31 false --09-30 Regenicin, Inc. 0001412659 No No Yes Smaller Reporting Company

157914

5500000 5500000 885000 885000 885000 885000

157911410

4600000

4000000 4000000

200000000

203039

290027

203039

295311

-203039

-280311

-5067

-4411

-5067

-1511

-17845

20586

8976

-5557

16924

-2313

-31293

-45729

-155446

33848

-13009

-11881

-168455

2010-07-21 2015-01-30 2014-11-07 2016-10-16

3600000

19201

7320

60592

40004

280961

275402

175000 175000

10000

20000 64958 42958 12000

2529238

2704875

885 885

10177515

-12773831

-12981937

-4428 -4428 0.001 0.001

0.001

4428360

1780508

1217622

0 0 Q1 8000 35250

15000

27250

-800

-180856

-282622

2000000

5284

44958

500

463837

481682

10000

2007-09-06

2011-12-21

2012-06-21

0.08

0.3123

175000 0 175000

-2441445

-2622301

87793 82574 1197000 807975

87793

82574

87793

82574

298476

300574

92389

300574

1707001

1852251

145250

40104 27070 686800 500108

3704412

2552775

3704412

2552775

-203039 -295311

-2900

P3Y

64622

2029-01-01

500

27750

19201

7320

218847

50392

-13009

37800

26690

Nevada P5Y 10000000 Amarantus can exercise this option at a cost of $10,000,000 plus a royalty of 5% on gross revenues in excess of $150 million.

0.08

Each share of Preferred Stock has an initial stated value of $1 and is convertible into shares of the Company’s common stock at the rate of 10 for 1. 153483050

208106

281822

4411

-2892

-11110

Windstar, Inc. was incorporated in the state of Nevada on September 6, 2007. On July 19, 2010, the Company amended its Articles of Incorporation to change the name of the Company to Regenicin, Inc. (“Regenicin”). In September 2013, Regenicin formed a new wholly-owned subsidiary for the sole purpose of conducting research in the State of Georgia (together, the “Company”). The subsidiary has no activity since its formation due to the lack of funding. The Company’s original business was the development of a purification device. Such business was assigned to the Company’s former management in July 2010. The Company adopted a new business plan and intended to develop and commercialize a potentially lifesaving technology by the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures.   The Company entered into a Know-How License and Stock Purchase Agreement (the “Know-How SPA”) with Lonza Walkersville, Inc. (“Lonza Walkersville”) on July 21, 2010. Pursuant to the terms of the Know-How SPA, the Company paid Lonza Walkersville $3,000,000 and, in exchange, the Company was to receive an exclusive license to use certain proprietary know-how and information necessary to develop and seek approval by the U.S. Food and Drug Administration (“FDA”) for the commercial sale of technology held by the Cutanogen Corporation (“Cutanogen”), a subsidiary of Lonza Walkersville. Additionally, pursuant to the terms of the Know-How SPA, the Company was entitled to receive certain related assistance and support from Lonza Walkersville upon payment of the $3,000,000. Under the Know-How SPA, once FDA approval was secured for the commercial sale of the technology, the Company would be entitled to acquire Cutanogen, Lonza Walkersville’s subsidiary, for $2,000,000 in cash. After prolonged attempts to negotiate disputes with Lonza Walkersville failed, on September 30, 2013, the Company filed a lawsuit against Lonza Walkersville, Lonza Group Ltd. and Lonza America, Inc. (“Lonza America”) in Fulton County Superior Court in the State of Georgia.   On November 7, 2014, the Company entered into an Asset Sale Agreement (the “Sale Agreement”) with Amarantus Bioscience Holdings, Inc., (“Amarantus”). Under the Sale Agreement, the Company agreed to sell to Amarantus all of its rights and claims in the litigation currently pending in the United States District Court for the District of New Jersey against Lonza Walkersville and Lonza America, Inc. (the “Lonza Litigation”). This includes all of the Cutanogen intellectual property rights and any Lonza manufacturing know-how technology. In addition, the Company agreed to sell the PermaDerm® trademark and related intellectual property rights associated with it. The purchase price paid by Amarantus was: (i) $3,600,000 in cash, and (ii) shares of common stock in Amarantus having a value of $3,000,000 at the date of the transaction.   The Company used the net proceeds of the transaction to fund development of cultured cell technology and to pursue approval of the products through the FDA as well as for general and administrative expenses. The Company has been developing its own unique cultured skin substitute since the Company received Lonza’s termination notice.

Interim Financial Statements:   The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended December 31, 2017 are not necessarily indicative of the results that may be expected for the year ending September 30, 2018. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended September 30, 2017, as filed with the Securities and Exchange Commission.   Going Concern:   The Company's consolidated financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred cumulative losses and has an accumulated deficit of approximately $13.0 million from inception, expects to incur further losses in the development of its business and has been dependent on funding operations through the issuance of convertible debt, private sale of equity securities, and the proceeds from the Asset Sale. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The Company used the proceeds from the Asset Sale to fund operations. Currently management plans to finance operations through the private or public placement of debt and/or equity securities. However, no assurance can be given at this time as to whether the Company will be able to obtain such financing. The consolidated financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.    Financial Instruments and Fair Value Measurement:   The Company measures fair value of its financial assets on a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:   • Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.   • Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable or inputs that can be corroborated by observable market data for substantially the full term of the assets or liabilities.   • Level 3 - Unobservable inputs which are supported by little or no market activity.   The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.   The carrying value of cash, prepaid expenses and other current assets, accounts payable, accrued expenses and all loans and notes payable in the Company’s consolidated balance sheets approximated their values as of December 31, 2017 and September 30, 2017 due to their short-term nature.   Common stock of Amarantus represents equity investments in common stock that the Company classifies as available for sale. Such investments are carried at fair value in the accompanying consolidated balance sheets. Fair value is determined under the guidelines of GAAP which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. Realized gains and losses, determined using the first-in, first-out (FIFO) method, are included in net income (loss). Unrealized gains and losses considered to be temporary are reported as other comprehensive income (loss) and are included in stockholders equity. Other than temporary declines in the fair value of investment is included in other income (expense) on the statement of operations.   The common stock of Amarantus is valued at the closing price reported on the active market on which the security is traded. This valuation methodology is considered to be using Level 1 inputs. The total value of Amarantus common stock at December 31, 2017 is $35,250. The unrealized gain (loss) for the three months ended December 31, 2017 and 2016 was $27,250 and $(800) net of income taxes, respectively, and was reported as a component of comprehensive loss.   Recently Issued Accounting Pronouncements:   In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities”. The new standard principally affects accounting standards for equity investments, financial liabilities where the fair value option has been elected, and the presentation and disclosure requirements for financial instruments. Upon the effective date of the new standards, all equity investments in unconsolidated entities, other than those accounted for using the equity method of accounting, will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification and therefore, no changes in fair value will be reported in other comprehensive income (loss) for equity securities with readily determinable fair values. The new guidance on the classification and measurement will be effective for public business entities in fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, and early adoption of certain items is permitted. The Company is currently evaluating the impact of adopting this guidance.   All other recent pronouncements issued by the FASB or other authoritative standards groups with future effective dates are either not applicable or are not expected to be significant to the consolidated financial statements of the Company.

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended December 31, 2017 are not necessarily indicative of the results that may be expected for the year ending September 30, 2018. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended September 30, 2017, as filed with the Securities and Exchange Commission.

The Company measures fair value of its financial assets on a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:   • Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.   • Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable or inputs that can be corroborated by observable market data for substantially the full term of the assets or liabilities.   • Level 3 - Unobservable inputs which are supported by little or no market activity.   The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.   The carrying value of cash, prepaid expenses and other current assets, accounts payable, accrued expenses and all loans and notes payable in the Company’s consolidated balance sheets approximated their values as of December 31, 2017 and September 30, 2017 due to their short-term nature.   Common stock of Amarantus represents equity investments in common stock that the Company classifies as available for sale. Such investments are carried at fair value in the accompanying consolidated balance sheets. Fair value is determined under the guidelines of GAAP which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. Realized gains and losses, determined using the first-in, first-out (FIFO) method, are included in net income (loss). Unrealized gains and losses considered to be temporary are reported as other comprehensive income (loss) and are included in stockholders equity. Other than temporary declines in the fair value of investment is included in other income (expense) on the statement of operations.   The common stock of Amarantus is valued at the closing price reported on the active market on which the security is traded. This valuation methodology is considered to be using Level 1 inputs. The total value of Amarantus common stock at December 31, 2017 is $35,250. The unrealized gain (loss) for the three months ended December 31, 2017 and 2016 was $27,250 and $(800) net of income taxes, respectively, and was reported as a component of comprehensive loss.

In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities”. The new standard principally affects accounting standards for equity investments, financial liabilities where the fair value option has been elected, and the presentation and disclosure requirements for financial instruments. Upon the effective date of the new standards, all equity investments in unconsolidated entities, other than those accounted for using the equity method of accounting, will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification and therefore, no changes in fair value will be reported in other comprehensive income (loss) for equity securities with readily determinable fair values. The new guidance on the classification and measurement will be effective for public business entities in fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, and early adoption of certain items is permitted. The Company is currently evaluating the impact of adopting this guidance.   All other recent pronouncements issued by the FASB or other authoritative standards groups with future effective dates are either not applicable or are not expected to be significant to the consolidated financial statements of the Company.

The Company expects to purchase “Closed Herd” collagen from Pure Med Farma, LLC (“PureMed”), a development stage company in which the company’s CEO and CFO are member - owners. The Company and Pure Med entered into a three year supply agreement on October 16, 2016 naming Pure Med as the exclusive provider of collagen to the Company. The Company has agreed to assist PureMed by providing consultants to work on certain tasks in order to gain FDA approval. Such consultants’ costs would be reimbursed by PureMed. On December 15, 2016, PureMed issued a note in the amount of $64,622 representing the advances for consultants through that date. Under the terms of the note, interest accrued at 8% per annum and was payable on or before December 15, 2017. The balance of the note plus accrued interest of $7,308 was repaid in full in May 2017. Loans Payable - Officer:   Loans payable - officer consists of the following:    • In September 2017, John Weber, the Company’s Chief Financial Officer, made an advance to the Company of $10,000. In November and December additional advances were made totaling $42,958. The loans do not bear interest and are due on demand.   • In September 2017, J. Roy Nelson, the Company’s Chief Science Officer, made an advance to the Company of $10,000. In November an additional advance was made in the amount of $2,000. The loans do not bear interest and are due on demand.

On December 21, 2011, the Company issued a $150,000 promissory note to an individual. The note bore interest so that the Company would repay $175,000 on the maturity date of June 21, 2012, which correlated to an effective rate of 31.23%. Additional interest of 10% was charged on any late payments. The note was not paid at the maturity date and the Company is incurring additional interest as described above. At both December 31, 2017 and September 30, 2017, the note balance was $175,000. Interest expense was $4,411 for both quarters ended December 31, 2017 and 2016. Accrued interest on the note was $96,800 and $92,389 as of December 31, 2017 and September 30, 2017, respectively, and is included in Accrued expenses - other in the accompanying balance sheet.

The Company did not incur current tax expense for the three months ended December 31, 2017 and 2016.   At December 31, 2017, the Company had available approximately $4.6 million of net operating loss carry forwards (“NOLs”) which expire in the years 2029 through 2037. However, the use of the NOLs generated prior to September 30, 2011 totaling $0.7 million is limited under Section 382 of the Internal Revenue Code. Section 382 of the Internal Revenue Code of 1986, as amended (the Code), imposes an annual limitation on the amount of taxable income that may be offset by a corporation’s NOLs if the corporation experiences an “ownership change” as defined in Section 382 of the Code.   On December 22, 2017, new tax legislation came into effect. The provisions are generally effective for years beginning on or after January 1, 2018. The most impactful item to the Company in the new law is the change in federal tax rate from 34% to 21%. This will reduce the gross deferred tax assets prior to existing full valuation allowance from an effective combined federal/state/local rate of 40% to an effective rate of 27%. The provision and disclosures for the period ended December 31, 2017 reflect the new tax legislation.   Significant components of the Company’s deferred tax assets at December 31, 2017 and September 30, 2017 are as follows:   <table cellspacing="0" cellpadding="0" align="center" style="font: 10pt Gotham Book; width: 50%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">December 31, 2017</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">September 30, 2017</td></tr> <tr style="vertical-align: bottom; background-color: #CCEECC"> <td style="width: 57%">Net operating loss carry forwards</td> <td style="width: 2%">$</td> <td style="width: 18%; text-align: right">1,217,622</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 2%">$</td> <td style="width: 18%; text-align: right">1,780,508</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Unrealized loss</td> <td> </td> <td style="text-align: right">807,975</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,197,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEECC"> <td>Stock based compensation</td> <td> </td> <td style="text-align: right">27,070</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">40,104</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Accrued expenses</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">500,108</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">686,800</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEECC"> <td>Total deferred tax assets</td> <td> </td> <td style="text-align: right">2,552,775</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,704,412</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Valuation allowance</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(2,552,775</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(3,704,412</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEECC"> <td style="padding-bottom: 2.5pt">Net deferred tax assets</td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Due to the uncertainty of their realization, a valuation allowance has been established for all of the income tax benefit for these deferred tax assets.   At both December 31, 2017 and September 30, 2017, the Company had no material unrecognized tax benefits and no adjustments to liabilities or operations were required. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company recognizes interest and penalties related to uncertain tax positions in general and administrative expense. As of December 31, 2017 and September 30, 2017 the Company has not recorded any provisions for accrued interest and penalties related to uncertain tax positions.   The Company files its federal income tax returns under a statute of limitations. The 2014 through 2017 tax years generally remain subject to examination by federal tax authorities.

<table cellspacing="0" cellpadding="0" align="center" style="font: 10pt Gotham Book; width: 50%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">December 31, 2017</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">September 30, 2017</td></tr> <tr style="vertical-align: bottom; background-color: #CCEECC"> <td style="width: 57%">Net operating loss carry forwards</td> <td style="width: 2%">$</td> <td style="width: 18%; text-align: right">1,229,726</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 2%">$</td> <td style="width: 18%; text-align: right">1,780,508</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Unrealized loss</td> <td> </td> <td style="text-align: right">807,975</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,197,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEECC"> <td>Stock based compensation</td> <td> </td> <td style="text-align: right">27,070</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">40,104</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Accrued expenses</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">500,108</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">686,800</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEECC"> <td>Total deferred tax assets</td> <td> </td> <td style="text-align: right">2,564,879</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,704,412</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Valuation allowance</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(2,564,879</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(3,704,412</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEECC"> <td style="padding-bottom: 2.5pt">Net deferred tax assets</td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

.21

.27

Preferred Stock:   Series A   At both December 31, 2017 and September 30, 2017, 885,000 shares of Series A Preferred Stock (“Series A Preferred”) were outstanding.   Series A Preferred pays a dividend of 8% per annum on the stated value and has a liquidation preference equal to the stated value of the shares ($885,000 liquidation preference as of December 31, 2017 and September 30, 2017 plus dividends in arrears as per below). Each share of Series A Preferred Stock has an initial stated value of $1 and is convertible into shares of the Company’s common stock at the rate of 10 for 1.   The Series A Preferred Stock was marketed through a private placement memorandum that included a reference to a ratchet provision which would have allowed the holders of the stock to claim a better conversion rate based on other stock transactions conducted by the Company during the three year period following the original issuance of the shares. The Certificate of Designation does not contain a ratchet provision. Certain of the stock related transactions consummated by the Company during this time period may have triggered this ratchet provision, and thus created a claim by holders of the Series A Preferred Stock who purchased based on this representation for a greater conversion rate than initially provided. The Company is currently negotiating with some of the remaining Series A holders regarding this claim and their conversation rate of their Series A Preferred Stock. Changes to the preferred stock conversion ratio may result in modification or extinguishment accounting. That may result in a deemed preferred stock dividend which would reduce net income available to common stockholders in the calculation of earnings per share. Certain of the smaller Series A holders have already converted or provided notice of conversion of their shares. In respect of this claim, the Company and its outside counsel determined that it is not possible to offer an opinion regarding the outcome. An adverse outcome could materially increase the accumulated deficit.   The dividends are cumulative commencing on the issue date when and if declared by the Board of Directors. As of December 31, 2017, and September 30, 2017, dividends in arrears were $481,682 ($.54 per share) and $463,837 ($.52 per share), respectively.   Series B   On January 23, 2012, the Company designated a new class of preferred stock called Series B Convertible Preferred Stock (“Series B Preferred”). Four million shares have been authorized with a liquidation preference of $2.00 per share. Each share of Series B Preferred is convertible into ten shares of common stock. Holders of Series B Convertible Preferred Stock have a right to a dividend (pro-rata to each holder) based on a percentage of the gross revenue earned by the Company in the United States, if any, and the number of outstanding shares of Series B Convertible Preferred Stock, as follows: Year 1 - Total Dividend to all Series B holders = .03 x Gross Revenue in the U.S. Year 2 - Total Dividend to all Series B holders = .02 x Gross Revenue in the U.S. Year 3 - Total Dividend to all Series B holders = .01 x Gross Revenue in the U.S. At December 31, 2017, no shares of Series B Preferred are outstanding.

On November 7, 2014, the Company entered into a Sale Agreement, as amended on January 30, 2015, with Amarantus. See Note 1. Under the Sale Agreement, the Company agreed to sell to Amarantus all of its rights and claims in the Lonza Litigation. These include all of the Cutanogen intellectual property rights and any Lonza manufacturing know-how technology. In addition, the Company had agreed to sell its PermaDerm® trademark and related intellectual property rights associated with it. The Company also granted to Amarantus an exclusive five (5) year option to license any engineered skin designed for the treatment of patients designated as severely burned by the FDA developed by the Company. Amarantus can exercise this option at a cost of $10,000,000 plus a royalty of 5% on gross revenues in excess of $150 million. As of December 31, 2017, the option has not been exercised.

The Company’s principal executive offices are located in Little Falls, New Jersey. The headquarters is located in the offices of McCoy Enterprises LLC, an entity controlled by Mr. McCoy. The office is attached to his residence but has its own entrances, restroom and kitchen facilities.   The Company also maintains an office at Carbon & Polymer Research Inc. ("CPR") in Pennington, New Jersey, which is the Company's materials and testing laboratory. An employee of the Company is an owner of CPR. On May 16, 2016, the Company entered into an agreement with CPR in which CPR will supply the collagen scaffolds used in the Company's production of the skin tissue. The contract contains a most favored customer clause guaranteeing the Company prices equal or lower than those charged to other customers. The Company has not yet made purchases from CPR.   No rent is charged for either premise.

Management has evaluated subsequent events through the date of this filing.

Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share gives effect to dilutive convertible securities, options, warrants and other potential common stock outstanding during the period; only in periods in which such effect is dilutive.   The following weighted average securities have been excluded from the calculation of net loss per share for the quarters ended December 31, 2017 and 2016, as the exercise price was greater than the average market price of the common shares:   <table cellspacing="0" cellpadding="0" align="center" style="width: 50%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="3" style="font: 10pt Gotham Book; text-align: justify"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 10pt Gotham Book; text-align: center">2017</td> <td style="padding-bottom: 1pt; font: 10pt Gotham Book"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 10pt Gotham Book; text-align: center">2016</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Gotham Book; width: 2%"> </td> <td style="font: 10pt Gotham Book; width: 32%">Warrants</td> <td style="padding-bottom: 1pt; font: 10pt Gotham Book; width: 2%"> </td> <td style="font: 10pt Gotham Book; width: 2%"> </td> <td style="font: 10pt Gotham Book; text-align: right; width: 27%">722,500</td> <td style="padding-bottom: 1pt; font: 10pt Gotham Book; width: 2%"> </td> <td style="padding-bottom: 1pt; font: 10pt Gotham Book; width: 2%"> </td> <td style="font: 10pt Gotham Book; width: 2%"> </td> <td style="font: 10pt Gotham Book; text-align: right; width: 27%">722,500</td> <td style="padding-bottom: 1pt; font: 10pt Gotham Book; width: 2%"> </td></tr> </table>   The following weighted average securities have been excluded from the calculation even though the exercise price was less than the average market price of the common shares because the effect of including these potential shares was anti-dilutive due to the net loss incurred during the quarters ended December 31, 2017 and 2016:   <table cellspacing="0" cellpadding="0" align="center" style="font: 10pt Gotham Book; width: 50%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2016</td></tr> <tr style="vertical-align: bottom; background-color: #CCEECC"> <td style="width: 55%; padding-bottom: 1pt; padding-left: 2.75pt; text-align: justify">Options</td> <td style="width: 1%"> </td> <td style="width: 20%; text-align: right">10,393,754</td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%"> </td> <td style="width: 20%; text-align: right">5,150,979</td> <td style="width: 1%; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 2.75pt; text-align: justify">Convertible Preferred Stock</td> <td> </td> <td style="text-align: right">8,850,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td> </td> <td style="text-align: right">8,850,000</td> <td style="padding-bottom: 1pt"> </td></tr> </table>   The effects of options and warrants on diluted earnings per share are reflected through the use of the treasury stock method and the excluded shares that are “in the money” are disclosed above in that manner.

<table cellspacing="0" cellpadding="0" align="center" style="font: 10pt " letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; width: 823px; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="3" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; line-height: normal; text-align: justify"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; line-height: normal; text-align: center">2017</td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; line-height: normal"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; line-height: normal; text-align: center">2016</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 204)"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; line-height: normal; width: 2%"> </td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; line-height: normal; width: 38%">Warrants</td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; line-height: normal; width: 2%"> </td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; line-height: normal; width: 2%"> </td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; line-height: normal; text-align: right; width: 26%">722,500</td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; line-height: normal; width: 1%"> </td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; line-height: normal; width: 1%"> </td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; line-height: normal; width: 1%"> </td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; line-height: normal; text-align: right; width: 26%">722,500</td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; line-height: normal; width: 1%"> </td></tr> </table> <table cellspacing="0" cellpadding="0" align="center" style="letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; width: 823px; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2016</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 204)"> <td style="width: 55%; padding-bottom: 1pt; padding-left: 2.75pt; text-align: justify">Options</td> <td style="width: 1%"> </td> <td style="width: 20%; text-align: right">10,393,754</td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%"> </td> <td style="width: 20%; text-align: right">5,150,979</td> <td style="width: 1%; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 2.75pt; text-align: justify">Convertible Preferred Stock</td> <td> </td> <td style="text-align: right">8,850,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td> </td> <td style="text-align: right">8,850,000</td> <td style="padding-bottom: 1pt"> </td></tr> </table> 5150979 10393754 8850000 8850000 722500 722500

150000

0.10 2.00 2.00

-225951

-299667

-0.00

153483050

EX-101.SCH 6 rgin-20171231.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEET link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEET (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME LOSS link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - THE COMPANY link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - DUE FROM RELATED PARTY link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - LOANS PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - BRIDGE FINANCING link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - STOCKHOLDERS DEFICIENCY link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - SALE OF ASSET link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - BASIS OF PRESENTATION (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - LOSS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - THE COMPANY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - BASIS OF PRESENTATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - LOSS PER SHARE - Schedule Of Income Loss per Common Share Exclusions (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - DUE FROM RELATED PARTY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - LOANS PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - BRIDGE FINANCING (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - INCOME TAXES - Schedule of Deferred Tax Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - STOCKHOLDERS DEFICIENCY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - SALE OF ASSET (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 rgin-20171231_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 rgin-20171231_def.xml XBRL DEFINITION FILE EX-101.LAB 9 rgin-20171231_lab.xml XBRL LABEL FILE Equity Components [Axis] Series A Series B Finite Lived Intangible Assets By Major Class [Axis] Know How SPA Notes Payable [Axis] Promissory Note 2 Earning Per Share [Axis] Exclusions - Diluted Calcs Sale of Assets [Axis] Sale Agmt Amendment Sale Agreement Related Party [Axis] Supply Agmt Exclusions - Diluted Calcs #2 Loan Payable [Axis] CFO CSO Exclusions - Calcs Exclusions - Calcs #2 Shareholder Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash Prepaid expenses and other current assets Common stock of Amarantus Corporation Total current assets Due from related party Total assets LIABILITIES AND STOCKHOLDERS' DEFICIENCY CURRENT LIABILITIES Accounts payable Accrued expenses - other Accrued salaries - officers Note payable - insurance financing Bridge financing Loan payable Loans payable - officer Total current and total liabilities STOCKHOLDERS' DEFICIENCY Series A 10% Convertible Preferred stock, $0.001 par value, 5,500,000 shares authorized; 885,000 issued and outstanding Common stock, $0.001 par value; 200,000,000 shares authorized; 157,911,410 issued and 153,483,050 outstanding Additional paid-in capital Accumulated deficit Accumulated other comprehensive income Less: treasury stock; 4,428,360 shares at par Total stockholders' deficiency Total liabilities and stockholders' deficiency Series A Preferred Stock, Par Value Series A Preferred Stock, Shares Authorized Series A Preferred Stock, Issued and outstanding Common Stock, Par Value Common Stock, Shares Authorized Common Stock, Issued Treasury Stock, Issued Income Statement [Abstract] Revenues Operating expenses Research and development General and administrative Total operating expenses Operating loss before other operating income Other operating income - reversal of accounts payable Loss from operations Other income (expenses) Interest expense Interest income Total other income (expenses) Net loss Preferred stock dividends Net loss available to common stockholders Loss per share Basic Loss per share Diluted Weighted average number of shares outstanding Basic Weighted average number of shares outstanding Diluted Consolidated Statements Of Comprehensive Income Loss Other comprehensive income (loss): Change in unrealized gain (loss) on available-for-sale securities, net of income taxes Comprehensive loss Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net loss Adjustments to reconcile net loss to net cash used in operating activities: Accrued interest on notes and loans payable Accrued Interest income on due from related party Reversal of accounts payable Changes in operating assets and liabilities Prepaid expenses and other current assets Accounts payable Accrued expenses Accrued salaries - officers Net cash used in operating activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds of loans from officers Repayments of notes payable - insurance financing Repayment of loans from officers Net cash provided by (used in ) financing activities NET DECREASE IN CASH CASH - BEGINNING OF PERIOD CASH - END OF PERIOD Supplemental disclosures of cash flow information: Cash paid for interest Cash paid for taxes Organization, Consolidation and Presentation of Financial Statements [Abstract] THE COMPANY BASIS OF PRESENTATION Accounting Policies [Abstract] LOSS PER SHARE Notes to Financial Statements DUE FROM RELATED PARTY LOANS PAYABLE Bridge Financing BRIDGE FINANCING Income Tax Disclosure [Abstract] INCOME TAXES Equity [Abstract] STOCKHOLDERS (DEFICIENCY) SALE OF ASSET Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Subsequent Events [Abstract] SUBSEQUENT EVENTS Interim Financial Statements Going Concern Research and development Income per share Financial Instruments and Fair Value Measurement Use of Estimates Stock-Based Compensation Income Taxes Recently Issued Accounting Pronouncements Schedule Of Income Loss per Common Share Exclusions Schedule of Income Loss per Common Share Exclusions Schedule of Deferred Tax Assets Statement [Table] Statement [Line Items] Finite-Lived Intangible Assets by Major Class [Axis] SaleOfAssetsAxis [Axis] Date of Incorporation State of Incorporation Date of Agreement Payment to Acquire Intangible Assets Payment to Acquire Subsidiary Purchase Price Basis Of Presentation Details Narrative Loss on other than temporary decline in fair value of investment Loss on other than a temporary decline in fair value of investment EarningPerShareAxis [Axis] Warrants Options Convertible preferred stock NotesPayableAxis [Axis] Term of Agreement Advances to Consultant Date of Note Interest rate Debt Instrument, Principal Maturity Date Debt Instrument, Accrued Interest Debt Instrument, Balance LoanPayableAxis [Axis] Loans payable - related parties Repayments of loans from officers Loan payable, balance Debt Instrument Interest Rate Additional interest rate if late Accrued expenses other Deferred tax asset attributable to: Net operating loss carryover Unrealized loss Stock based compensation Accrued expenses Total deferred tax assets Valuation allowance Net deferred tax asset Operating Loss Carryforwards Carryforward Expiration Date Statutory federal income tax rate Adjustment of valuation allowance Shareholders' Equity Class [Axis] Dividend per annum EX-101.PRE 10 rgin-20171231_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Dec. 31, 2017	Feb. 12, 2018
Document And Entity Information
Entity Registrant Name	Regenicin, Inc.
Entity Central Index Key	0001412659
Document Type	10-Q
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		153,483,050
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2017

XML 12 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEET - USD ($)	Dec. 31, 2017	Sep. 30, 2017
CURRENT ASSETS
Cash	$ 7,320	$ 19,201
Prepaid expenses and other current assets	40,004	60,592
Common stock of Amarantus Corporation	35,250	8,000
Total current assets	82,574	87,793
Due from related party
Total assets	82,574	87,793
CURRENT LIABILITIES
Accounts payable	275,402	280,961
Accrued expenses - other	300,574	298,476
Accrued salaries - officers	1,852,251	1,707,001
Note payable - insurance financing	26,690	37,800
Bridge financing	175,000	175,000
Loan payable	10,000	10,000
Loans payable - officer	64,958	20,000
Total current and total liabilities	2,704,875	2,529,238
STOCKHOLDERS' DEFICIENCY
Series A 10% Convertible Preferred stock, $0.001 par value, 5,500,000 shares authorized; 885,000 issued and outstanding	885	885
Common stock, $0.001 par value; 200,000,000 shares authorized; 157,911,410 issued and 153,483,050 outstanding	157,914	157,914
Additional paid-in capital	10,177,515	10,177,515
Accumulated deficit	(12,981,937)	(12,773,831)
Accumulated other comprehensive income	27,750	500
Less: treasury stock; 4,428,360 shares at par	(4,428)	(4,428)
Total stockholders' deficiency	(2,622,301)	(2,441,445)
Total liabilities and stockholders' deficiency	$ 82,574	$ 87,793

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEET (Parenthetical) - $ / shares	Dec. 31, 2017	Sep. 30, 2017
Statement of Financial Position [Abstract]
Series A Preferred Stock, Par Value	$ 0.001	$ 0.001
Series A Preferred Stock, Shares Authorized	5,500,000	5,500,000
Series A Preferred Stock, Issued and outstanding	885,000	885,000
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Issued	157,911,410	157,911,410
Treasury Stock, Issued	4,428,360	4,428,360

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Revenues
Operating expenses
Research and development		5,284
General and administrative	203,039	290,027
Total operating expenses	203,039	295,311
Operating loss before other operating income	(203,039)	(295,311)
Loss from operations	(203,039)	(280,311)
Other income (expenses)
Interest expense	(5,067)	(4,411)
Interest income		2,900
Total other income (expenses)	(5,067)	(1,511)
Net loss	(208,106)	(281,822)
Preferred stock dividends	(17,845)	(17,845)
Net loss available to common stockholders	$ (225,951)	$ (299,667)
Loss per share Basic	$ (0.00)	$ (0.00)
Loss per share Diluted	$ (0.00)	$ (0.00)
Weighted average number of shares outstanding Basic	153,483,050	153,483,050
Weighted average number of shares outstanding Diluted	153,483,050	153,483,050

XML 15 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME LOSS - USD ($)	3 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Consolidated Statements Of Comprehensive Income Loss
Net loss	$ (208,106)	$ (281,822)
Other comprehensive income (loss):
Change in unrealized gain (loss) on available-for-sale securities, net of income taxes	27,250	(800)
Comprehensive loss	$ (180,856)	$ (282,622)

XML 16 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	Dec. 31, 2017	Dec. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ 208,106	$ 281,822
Adjustments to reconcile net loss to net cash used in operating activities:
Accrued interest on notes and loans payable	4,411	4,411
Accrued Interest income on due from related party		(2,892)
Reversal of accounts payable		(15,000)
Changes in operating assets and liabilities
Prepaid expenses and other current assets	20,586	8,976
Accounts payable	(5,557)	16,924
Accrued expenses	(2,313)	(31,293)
Accrued salaries - officers	145,250	145,250
Net cash used in operating activities	(45,729)	(155,446)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds of loans from officers	44,958
Repayments of notes payable - insurance financing	(11,110)
Repayment of loans from officers		(13,009)
Net cash provided by (used in ) financing activities	33,848	(13,009)
NET DECREASE IN CASH	(11,881)	(168,455)
CASH - BEGINNING OF PERIOD	19,201	218,847
CASH - END OF PERIOD	7,320	50,392
Supplemental disclosures of cash flow information:
Cash paid for interest
Cash paid for taxes	$ 500

XML 17 R7.htm IDEA: XBRL DOCUMENT

THE COMPANY

3 Months Ended

Dec. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

THE COMPANY

XML 18 R8.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION

3 Months Ended

Dec. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BASIS OF PRESENTATION

Interim Financial Statements:

Going Concern:

Financial Instruments and Fair Value Measurement:

The Company measures fair value of its financial assets on a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

• Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

• Level 3 - Unobservable inputs which are supported by little or no market activity.

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

Recently Issued Accounting Pronouncements:

XML 19 R9.htm IDEA: XBRL DOCUMENT

LOSS PER SHARE

3 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

LOSS PER SHARE

			2017				2016
	Warrants			722,500				722,500

	2017		2016
Options		10,393,754		5,150,979
Convertible Preferred Stock		8,850,000		8,850,000

XML 20 R10.htm IDEA: XBRL DOCUMENT

DUE FROM RELATED PARTY	3 Months Ended
DUE FROM RELATED PARTY	Dec. 31, 2017
Notes to Financial Statements
DUE FROM RELATED PARTY	The Company expects to purchase “Closed Herd” collagen from Pure Med Farma, LLC (“PureMed”), a development stage company in which the company’s CEO and CFO are member - owners. The Company and Pure Med entered into a three year supply agreement on October 16, 2016 naming Pure Med as the exclusive provider of collagen to the Company. The Company has agreed to assist PureMed by providing consultants to work on certain tasks in order to gain FDA approval. Such consultants’ costs would be reimbursed by PureMed. On December 15, 2016, PureMed issued a note in the amount of $64,622 representing the advances for consultants through that date. Under the terms of the note, interest accrued at 8% per annum and was payable on or before December 15, 2017. The balance of the note plus accrued interest of $7,308 was repaid in full in May 2017.

XML 21 R11.htm IDEA: XBRL DOCUMENT

LOANS PAYABLE

3 Months Ended

Dec. 31, 2017

Notes to Financial Statements

LOANS PAYABLE

Loans Payable - Officer:

Loans payable - officer consists of the following:

XML 22 R12.htm IDEA: XBRL DOCUMENT

BRIDGE FINANCING	3 Months Ended
BRIDGE FINANCING	Dec. 31, 2017
Bridge Financing
BRIDGE FINANCING	On December 21, 2011, the Company issued a $150,000 promissory note to an individual. The note bore interest so that the Company would repay $175,000 on the maturity date of June 21, 2012, which correlated to an effective rate of 31.23%. Additional interest of 10% was charged on any late payments. The note was not paid at the maturity date and the Company is incurring additional interest as described above. At both December 31, 2017 and September 30, 2017, the note balance was $175,000. Interest expense was $4,411 for both quarters ended December 31, 2017 and 2016. Accrued interest on the note was $96,800 and $92,389 as of December 31, 2017 and September 30, 2017, respectively, and is included in Accrued expenses - other in the accompanying balance sheet.

XML 23 R13.htm IDEA: XBRL DOCUMENT

INCOME TAXES

3 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

INCOME TAXES

The Company did not incur current tax expense for the three months ended December 31, 2017 and 2016.

Significant components of the Company’s deferred tax assets at December 31, 2017 and September 30, 2017 are as follows:

	December 31, 2017			September 30, 2017
Net operating loss carry forwards	$	1,217,622		$	1,780,508
Unrealized loss		807,975			1,197,000
Stock based compensation		27,070			40,104
Accrued expenses		500,108			686,800
Total deferred tax assets		2,552,775			3,704,412
Valuation allowance		(2,552,775	)		(3,704,412	)
Net deferred tax assets	$	—		$	—

Due to the uncertainty of their realization, a valuation allowance has been established for all of the income tax benefit for these deferred tax assets.

The Company files its federal income tax returns under a statute of limitations. The 2014 through 2017 tax years generally remain subject to examination by federal tax authorities.

XML 24 R14.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS DEFICIENCY

3 Months Ended

Dec. 31, 2017

Equity [Abstract]

STOCKHOLDERS (DEFICIENCY)

Preferred Stock:

Series A

At both December 31, 2017 and September 30, 2017, 885,000 shares of Series A Preferred Stock (“Series A Preferred”) were outstanding.

Series B

XML 25 R15.htm IDEA: XBRL DOCUMENT

SALE OF ASSET	3 Months Ended
SALE OF ASSET	Dec. 31, 2017
Notes to Financial Statements
SALE OF ASSET	On November 7, 2014, the Company entered into a Sale Agreement, as amended on January 30, 2015, with Amarantus. See Note 1. Under the Sale Agreement, the Company agreed to sell to Amarantus all of its rights and claims in the Lonza Litigation. These include all of the Cutanogen intellectual property rights and any Lonza manufacturing know-how technology. In addition, the Company had agreed to sell its PermaDerm® trademark and related intellectual property rights associated with it. The Company also granted to Amarantus an exclusive five (5) year option to license any engineered skin designed for the treatment of patients designated as severely burned by the FDA developed by the Company. Amarantus can exercise this option at a cost of $10,000,000 plus a royalty of 5% on gross revenues in excess of $150 million. As of December 31, 2017, the option has not been exercised.

XML 26 R16.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

3 Months Ended

Dec. 31, 2017

RELATED PARTY TRANSACTIONS

No rent is charged for either premise.

XML 27 R17.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS	3 Months Ended
SUBSEQUENT EVENTS	Dec. 31, 2017
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	Management has evaluated subsequent events through the date of this filing.

XML 28 R18.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION (Policies)

3 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Interim Financial Statements

Going Concern

Income per share

			2017				2016
	Warrants			722,500				722,500

	2017		2016
Options		10,393,754		5,150,979
Convertible Preferred Stock		8,850,000		8,850,000

Financial Instruments and Fair Value Measurement

The Company measures fair value of its financial assets on a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

• Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

• Level 3 - Unobservable inputs which are supported by little or no market activity.

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

Recently Issued Accounting Pronouncements

XML 29 R19.htm IDEA: XBRL DOCUMENT

LOSS PER SHARE (Tables)

3 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Schedule Of Income Loss per Common Share Exclusions

			2017				2016
	Warrants			722,500				722,500

Schedule of Income Loss per Common Share Exclusions

	2017		2016
Options		10,393,754		5,150,979
Convertible Preferred Stock		8,850,000		8,850,000

XML 30 R20.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Tables)

3 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Schedule of Deferred Tax Assets

	December 31, 2017			September 30, 2017
Net operating loss carry forwards	$	1,229,726		$	1,780,508
Unrealized loss		807,975			1,197,000
Stock based compensation		27,070			40,104
Accrued expenses		500,108			686,800
Total deferred tax assets		2,564,879			3,704,412
Valuation allowance		(2,564,879	)		(3,704,412	)
Net deferred tax assets	$	—		$	—

XML 31 R21.htm IDEA: XBRL DOCUMENT

THE COMPANY (Details Narrative)	3 Months Ended
THE COMPANY (Details Narrative)	Dec. 31, 2017 USD ($)
Date of Incorporation	Sep. 06, 2007
State of Incorporation	Nevada
Sale Agreement
Date of Agreement	Nov. 07, 2014
Purchase Price	$ 3,600,000
Know How SPA
Date of Agreement	Jul. 21, 2010
Payment to Acquire Subsidiary	$ 2,000,000

XML 32 R22.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION (Details Narrative) - USD ($)	3 Months Ended
BASIS OF PRESENTATION (Details Narrative) - USD ($)	Dec. 31, 2017	Dec. 31, 2016	Sep. 30, 2017
Basis Of Presentation Details Narrative
Common stock of Amarantus Corporation	$ 35,250		$ 8,000
Change in unrealized gain (loss) on available-for-sale securities, net of income taxes	27,250	$ (800)
Accumulated deficit	$ (12,981,937)		$ (12,773,831)

XML 33 R23.htm IDEA: XBRL DOCUMENT

LOSS PER SHARE - Schedule Of Income Loss per Common Share Exclusions (Details) - shares	Dec. 31, 2017	Dec. 31, 2016
Exclusions - Calcs
Warrants	722,500
Exclusions - Diluted Calcs
Warrants		722,500
Exclusions - Calcs #2
Options	10,393,754
Convertible preferred stock	8,850,000
Exclusions - Diluted Calcs #2
Options		5,150,979
Convertible preferred stock		8,850,000

XML 34 R24.htm IDEA: XBRL DOCUMENT

DUE FROM RELATED PARTY (Details Narrative) - USD ($)	3 Months Ended
DUE FROM RELATED PARTY (Details Narrative) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Interest income		$ 2,900
Supply Agmt
Date of Agreement		Oct. 16, 2016
Term of Agreement		3 years
Advances to Consultant		$ 64,622
Interest rate		8.00%
Debt Instrument, Balance		$ 0

XML 35 R25.htm IDEA: XBRL DOCUMENT

LOANS PAYABLE (Details Narrative) - USD ($)	3 Months Ended
LOANS PAYABLE (Details Narrative) - USD ($)	Dec. 31, 2017	Dec. 31, 2016	Sep. 30, 2017
Loan payable	$ 10,000		$ 10,000
Loans payable - related parties	64,958		$ 20,000
Repayments of loans from officers	44,958
Shareholder
Loan payable	10,000	10,000
Loan payable, balance	10,000	$ 10,000
CFO
Loans payable - related parties	42,958
CSO
Loans payable - related parties	$ 12,000

XML 36 R26.htm IDEA: XBRL DOCUMENT

BRIDGE FINANCING (Details Narrative) - USD ($)	3 Months Ended
BRIDGE FINANCING (Details Narrative) - USD ($)	Dec. 31, 2017	Dec. 31, 2016	Sep. 30, 2017
Accrued expenses other	$ 300,574		$ 298,476
Interest expense	$ (5,067)	$ (4,411)
Promissory Note 2
Date of Note	Dec. 21, 2011
Debt Instrument	$ 150,000
Maturity Date	Jun. 21, 2012
Interest Rate	31.23%
Additional interest rate if late	10.00%
Debt Instrument, Balance	$ 175,000		175,000
Accrued expenses other	300,574		$ 92,389
Interest expense	$ (4,411)	$ (4,411)

XML 37 R27.htm IDEA: XBRL DOCUMENT

INCOME TAXES - Schedule of Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2017	Sep. 30, 2017
Deferred tax asset attributable to:
Net operating loss carryover	$ 1,217,622	$ 1,780,508
Unrealized loss	807,975	1,197,000
Stock based compensation	27,070	40,104
Accrued expenses	500,108	686,800
Total deferred tax assets	2,552,775	3,704,412
Valuation allowance	(2,552,775)	(3,704,412)
Net deferred tax asset

XML 38 R28.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details Narrative)	3 Months Ended
INCOME TAXES (Details Narrative)	Dec. 31, 2017 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Operating Loss Carryforwards	$ 4,600,000
Carryforward Expiration Date	Jan. 01, 2029
Statutory federal income tax rate	21.00%
Adjustment of valuation allowance	27.00%

XML 39 R29.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS DEFICIENCY (Details Narrative) - USD ($)	3 Months Ended
STOCKHOLDERS DEFICIENCY (Details Narrative) - USD ($)	Dec. 31, 2017	Sep. 30, 2017
Series A Preferred Stock, Issued and outstanding	885,000	885,000
Common stock, Issued	157,911,410	157,911,410
Series A
Dividend per annum	8.00%
Dividend Stated Value, Description	Each share of Preferred Stock has an initial stated value of $1 and is convertible into shares of the Company’s common stock at the rate of 10 for 1.
Dividends payable	$ 481,682	$ 463,837
Series A Preferred Stock, Issued and outstanding	885,000	885,000
Series B
Series B Preferred Stock, Shares Authorized	4,000,000	4,000,000
Series B Preferred Stock, Outstanding	0	0
Series B Preferred Stock, Liquidation Preference	$ 2.00	$ 2.00

XML 40 R30.htm IDEA: XBRL DOCUMENT

SALE OF ASSET (Details Narrative)	3 Months Ended
SALE OF ASSET (Details Narrative)	Dec. 31, 2017 USD ($)
Sale Agreement
Date of Agreement	Nov. 07, 2014
Option to License IP, Term	5 years
Option to License IP, Cost	$ 10,000,000
Option to License IP, Description	Amarantus can exercise this option at a cost of $10,000,000 plus a royalty of 5% on gross revenues in excess of $150 million.
Sale Agmt Amendment
Date of Agreement	Jan. 30, 2015

EXCEL 41 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 42 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 43 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 45 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 29 131 1 false 14 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://RGIN/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - CONSOLIDATED BALANCE SHEET Sheet http://RGIN/role/ConsolidatedBalanceSheet CONSOLIDATED BALANCE SHEET Statements 2 false false R3.htm 00000003 - Statement - CONSOLIDATED BALANCE SHEET (Parenthetical) Sheet http://RGIN/role/ConsolidatedBalanceSheetParenthetical CONSOLIDATED BALANCE SHEET (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://RGIN/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME LOSS Sheet http://RGIN/role/ConsolidatedStatementsOfComprehensiveIncomeLoss CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME LOSS Statements 5 false false R6.htm 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://RGIN/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 00000007 - Disclosure - THE COMPANY Sheet http://RGIN/role/Company THE COMPANY Notes 7 false false R8.htm 00000008 - Disclosure - BASIS OF PRESENTATION Sheet http://RGIN/role/BasisOfPresentation BASIS OF PRESENTATION Notes 8 false false R9.htm 00000009 - Disclosure - LOSS PER SHARE Sheet http://RGIN/role/LossPerShare LOSS PER SHARE Notes 9 false false R10.htm 00000010 - Disclosure - DUE FROM RELATED PARTY Sheet http://RGIN/role/DueFromRelatedParty DUE FROM RELATED PARTY Notes 10 false false R11.htm 00000011 - Disclosure - LOANS PAYABLE Sheet http://RGIN/role/LoansPayable LOANS PAYABLE Notes 11 false false R12.htm 00000012 - Disclosure - BRIDGE FINANCING Sheet http://RGIN/role/BridgeFinancing BRIDGE FINANCING Notes 12 false false R13.htm 00000013 - Disclosure - INCOME TAXES Sheet http://RGIN/role/IncomeTaxes INCOME TAXES Notes 13 false false R14.htm 00000014 - Disclosure - STOCKHOLDERS DEFICIENCY Sheet http://RGIN/role/StockholdersDeficiency STOCKHOLDERS DEFICIENCY Notes 14 false false R15.htm 00000015 - Disclosure - SALE OF ASSET Sheet http://RGIN/role/SaleOfAsset SALE OF ASSET Notes 15 false false R16.htm 00000016 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://RGIN/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 16 false false R17.htm 00000017 - Disclosure - SUBSEQUENT EVENTS Sheet http://RGIN/role/SubsequentEvents SUBSEQUENT EVENTS Notes 17 false false R18.htm 00000018 - Disclosure - BASIS OF PRESENTATION (Policies) Sheet http://RGIN/role/BasisOfPresentationPolicies BASIS OF PRESENTATION (Policies) Policies 18 false false R19.htm 00000019 - Disclosure - LOSS PER SHARE (Tables) Sheet http://RGIN/role/LossPerShareTables LOSS PER SHARE (Tables) Tables http://RGIN/role/LossPerShare 19 false false R20.htm 00000020 - Disclosure - INCOME TAXES (Tables) Sheet http://RGIN/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://RGIN/role/IncomeTaxes 20 false false R21.htm 00000021 - Disclosure - THE COMPANY (Details Narrative) Sheet http://RGIN/role/CompanyDetailsNarrative THE COMPANY (Details Narrative) Details http://RGIN/role/Company 21 false false R22.htm 00000022 - Disclosure - BASIS OF PRESENTATION (Details Narrative) Sheet http://RGIN/role/BasisOfPresentationDetailsNarrative BASIS OF PRESENTATION (Details Narrative) Details http://RGIN/role/BasisOfPresentationPolicies 22 false false R23.htm 00000023 - Disclosure - LOSS PER SHARE - Schedule Of Income Loss per Common Share Exclusions (Details) Sheet http://RGIN/role/LossPerShare-ScheduleOfIncomeLossPerCommonShareExclusionsDetails LOSS PER SHARE - Schedule Of Income Loss per Common Share Exclusions (Details) Details 23 false false R24.htm 00000024 - Disclosure - DUE FROM RELATED PARTY (Details Narrative) Sheet http://RGIN/role/DueFromRelatedPartyDetailsNarrative DUE FROM RELATED PARTY (Details Narrative) Details http://RGIN/role/DueFromRelatedParty 24 false false R25.htm 00000025 - Disclosure - LOANS PAYABLE (Details Narrative) Sheet http://RGIN/role/LoansPayableDetailsNarrative LOANS PAYABLE (Details Narrative) Details http://RGIN/role/LoansPayable 25 false false R26.htm 00000026 - Disclosure - BRIDGE FINANCING (Details Narrative) Sheet http://RGIN/role/BridgeFinancingDetailsNarrative BRIDGE FINANCING (Details Narrative) Details http://RGIN/role/BridgeFinancing 26 false false R27.htm 00000027 - Disclosure - INCOME TAXES - Schedule of Deferred Tax Assets (Details) Sheet http://RGIN/role/IncomeTaxes-ScheduleOfDeferredTaxAssetsDetails INCOME TAXES - Schedule of Deferred Tax Assets (Details) Details 27 false false R28.htm 00000028 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://RGIN/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://RGIN/role/IncomeTaxesTables 28 false false R29.htm 00000029 - Disclosure - STOCKHOLDERS DEFICIENCY (Details Narrative) Sheet http://RGIN/role/StockholdersDeficiencyDetailsNarrative STOCKHOLDERS DEFICIENCY (Details Narrative) Details http://RGIN/role/StockholdersDeficiency 29 false false R30.htm 00000030 - Disclosure - SALE OF ASSET (Details Narrative) Sheet http://RGIN/role/SaleOfAssetDetailsNarrative SALE OF ASSET (Details Narrative) Details http://RGIN/role/SaleOfAsset 30 false false All Reports Book All Reports rgin-20171231.xml rgin-20171231.xsd rgin-20171231_cal.xml rgin-20171231_def.xml rgin-20171231_lab.xml rgin-20171231_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 47 0001662252-18-000034-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001662252-18-000034-xbrl.zip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end